Holen Sie sich die Stockscreener-App
29.53
0.54%
0.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$29.36
Offen:
$29.07
24-Stunden-Volumen:
506.67K
Relative Volume:
0.28
Marktkapitalisierung:
$2.85B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-4.5641
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
+1.76%
1M Leistung:
+11.86%
6M Leistung:
-30.69%
1J Leistung:
-48.26%
1-Tages-Spanne:
$28.85
$29.56
1-Wochen-Bereich:
$28.85
$30.10
52-Wochen-Spanne:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
29.54 | 2.86B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.29 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
601.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.18 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.54 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.01 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Will Ultragenyx Pharmaceutical Inc. Recover After Recent Decline2025 Fundamental Recap & Daily Profit Maximizing Trade Tips - newsyoung.net
Ultragenyx starts FDA marketing application process for its gene therapy - MSN
Machine Learning Models Forecast Ultragenyx Pharmaceutical Inc. UptickBear Alert & Reliable Breakout Forecasts - kangso.co.kr
Ultragenyx Initiates Rolling Submission of Biologics License Application to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia - MarketScreener
Ultragenyx Initiates Rolling BLA Submission for DTX401 Gene Therapy - AInvest
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa Treatment. - AInvest
Ultragenyx initiates rolling submission of BLA to U.S. FDA for DTX401 - TipRanks
Chartists See Breakout Potential in Ultragenyx Pharmaceutical Inc.July 2025 Weekly Recap & AI Enhanced Trade Execution Alerts - 선데이타임즈
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewswire
Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy - TradingView
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt - 富途牛牛
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Ultragenyx Begins FDA Marketing Application for DTX401 Gene Therapy for GSD Type Ia - AInvest
Ultragenyx Begins FDA Application for DTX401 Gene Therapy - TipRanks
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Neuren Pharma, Anavex Life Sciences, Edison Pharma, Novartis, Ultragenyx Pharma, GW Pharma, Q-State - Barchart.com
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy By Investing.com - Investing.com Nigeria
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy - Investing.com
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy - MarketScreener
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa. - AInvest
Ultragenyx Initiates Rolling Submission of Biologics - GlobeNewswire
Ultragenyx Initiates Rolling Submission of Biologics License Application for DTX401 AAV Gene Therapy to Treat GSDIa - AInvest
64% Treatment Success: Ultragenyx's Gene Therapy DTX401 Advances FDA Review for Rare Disease GSDIa - Stock Titan
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome - MSN
Pomerantz LLP investigates Ultragenyx Pharmaceutical securities fraud claims. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
Will earnings trigger a reversal in Ultragenyx Pharmaceutical Inc.Trade Risk Report & Free High Return Stock Watch Alerts - Newser
Why Ultragenyx (RARE) Is Up 7.8% After Reporting Narrowed Losses and Higher Q2 Revenue - simplywall.st
Will Ultragenyx Pharmaceutical Inc. bounce back from current supportJuly 2025 Market Mood & Accurate Intraday Trade Tips - Newser
How high can Ultragenyx Pharmaceutical Inc. stock goEarnings Overview Report & Reliable Intraday Trade Plans - Newser
Price Clustering Detected in Ultragenyx Pharmaceutical Inc. StockWeekly Trade Summary & Safe Investment Capital Preservation Plans - sundaytimes.kr
Ultragenyx Pharmaceutical Inc. Shows Support at Fibonacci LevelWeekly Risk Summary & Community Verified Watchlist Alerts - metal.it
Navigating Legal Storms in Biotech: The Ultragenyx Case and Investor Caution - AInvest
Ultragenyx Pharmaceutical faces securities fraud investigation. - AInvest
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Trade Entry Summary & Verified Short-Term Plans - Newser
How sentiment analysis helps forecast Ultragenyx Pharmaceutical Inc.2025 Risk Factors & Safe Capital Allocation Plans - Newser
Long term hold vs stop loss in Ultragenyx Pharmaceutical Inc.July 2025 Trends & Fast Gaining Stock Strategy Reports - Newser
Is Ultragenyx Pharmaceutical Inc. the Top Chart Pick This WeekMarket Volume Summary & Free Weekly Watchlist of Top Performers - 선데이타임즈
What are analysts’ price targets for Ultragenyx Pharmaceutical Inc.July 2025 Action & Verified Chart Pattern Trade Signals - sundaytimes.kr
RSI Reset May Fuel Rebound in Ultragenyx Pharmaceutical Inc.Wall Street Watch & Free AI Powered Buy and Sell Recommendations - newsyoung.net
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - MSN
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):